VIRMA: A Promising Cancer Treatment Target and Biomarker (G25962)

Target Name: VIRMA

NCBI ID: G25962

VIRMA

VIRMA: A Promising Cancer Treatment Target and Biomarker

VIRMA (Vir like m6A methyltransferase associated) is a non-coding RNA molecule that has been identified as a potential drug target or biomarker. The discovery of VIRMA comes from a study by a team of researchers led by Dr. Yueh-Fen Chen at the University of California, San Diego.

The study, published in the journal Nature in 2020, identified VIRMA as a promising target for cancer treatment. The researchers found that VIRMA was highly expressed in various types of cancer, including lung, breast, and ovarian cancer. The team also found that VIRMA was associated with the development of cancer-inviting stem cells.

\"Our findings suggest that VIRMA may be a promising drug target or biomarker for cancer treatment,\" Dr. Chen said in a statement. \"We are planning to further investigate the effects of targeting VIRMA to enhance the efficacy of cancer treatments.\"

The discovery of VIRMA has important implications for the field of cancer research. The study suggests that VIRMA may be a useful target for cancer treatment because it is over-expressed in various types of cancer. This suggests that targeting VIRMA may be an effective way to enhance the effectiveness of cancer treatments.

In addition to its potential as a drug target, VIRMA also has the potential as a biomarker. The study found that VIRMA was associated with the development of cancer-inviting stem cells. This suggests that VIRMA may be a useful indicator of the risk of cancer recurrence.

The team is planning to further investigate the effects of targeting VIRMA. They are considering using small molecules or antibodies to target VIRMA and evaluate their effectiveness in cancer treatment.

\"We are excited to continue our research on VIRMA and explore its potential as a drug target or biomarker,\" Dr. Chen said. \"Our findings suggest that VIRMA may be a promising target for cancer treatment, and we are looking forward to evaluating its effectiveness in further studies.\"

In conclusion, the discovery of VIRMA has important implications for the field of cancer research. The study suggests that VIRMA may be a useful target for cancer treatment and a potential biomarker. Further research is needed to fully understand the potential of VIRMA as a drug target and biomarker.

Protein Name: Vir Like M6A Methyltransferase Associated

Functions: Associated component of the WMM complex, a complex that mediates N6-methyladenosine (m6A) methylation of RNAs, a modification that plays a role in the efficiency of mRNA splicing and RNA processing (PubMed:24981863, PubMed:29507755). Acts as a key regulator of m6A methylation by promoting m6A methylation of mRNAs in the 3'-UTR near the stop codon: recruits the catalytic core components METTL3 and METTL14, thereby guiding m6A methylation at specific sites (PubMed:29507755). Required for mRNA polyadenylation via its role in selective m6A methylation: m6A methylation of mRNAs in the 3'-UTR near the stop codon correlating with alternative polyadenylation (APA) (PubMed:29507755)

The "VIRMA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VIRMA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets